Brain Storm: David Berry Profile in Boston Magazine

Brain Storm: David Berry Profile in Boston Magazine

April 20, 2011

"David Berry is one of the most brilliant thinkers you’ve never heard of. Starting in 2012 he’s going to eliminate our dependence on fossil fuels using little more than algae. (Okay, it’s technically cyanobacteria, but you know what we mean.) He might have done it sooner, but he’s also working on curing cancer and eradicating global hunger."

Excerpts from Boston Magazine story. 

Click Boston Magazine logo to view full story.

Joule Unlimited, Inc.

On the hunt for green-tech game changers

On the hunt for green-tech game changers

April 22, 2011

In a CNET NEWS story, Flagship's Noubar Afeyan was quoted discussing Joule Unlimited and the pace and scale of green technology innovation at the Yale Climate and Energy Institute's annual conference.

Click here to view the full story on cnet.

TARIS Biomedical, Inc.

TARIS CLOSES $18.3 MILLION SERIES B FINANCING

TARIS CLOSES $18.3 MILLION SERIES B FINANCING

April 13, 2011

Lexington, MA – TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases, announced today that it has raised $18.3 million of new capital in connection with its Series B equity financing. Third Rock Ventures, a new investor, led the round and all existing TARIS investors, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners, participated. The company’s prior bridge financing was also converted into equity in connection with the round.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Appoints Henri A. Termeer to its Board of Directors

AVEO Pharmaceuticals Appoints Henri A. Termeer to its Board of Directors

April 12, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the appointment of industry veteran Henri A. Termeer, outgoing chairman, president and chief executive officer of Genzyme Corporation, to its Board of Directors.

Ensemble Therapeutics Corporation

Ensemble Therapeutics Achieves Milestone in Bristol-Myers Squibb Collaboration

Ensemble Therapeutics Achieves Milestone in Bristol-Myers Squibb Collaboration

April 12, 2011

Major Progress Developing Ensemblins Against Challenging Drug Targets Yields Payment to Ensemble and Transfer of Successful Program to BMS

Macrocycle Platform Reaches New Levels of Productivity against Challenging Drug Targets

Seventh Sense Biosystems, Inc.

Seventh Sense Biosystems Receives Gold Medal Edison Award

Seventh Sense Biosystems Receives Gold Medal Edison Award

April 8, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seventh Sense Biosystems, Inc., an early stage, venture-backed company developing a new generation of health diagnostics products, announced today that its Touch Activated Phlebotomy™ (TAP) technology has received the Gold Medal Award from The Edison Awards™ in the Science and Medicine – Diagnostic Aids Segment. These annual awards recognize innovation, creativity and ingenuity. 

Mascoma Corporation

Ethanol Industry Hoping for Surge

Ethanol Industry Hoping for Surge

March 31, 2011

 

Flagship portfolio company, Mascoma, featured in The New York Times:

"Another biofuels company, Mascoma, plans a $350 million, 40 million-gallon-a-year cellulosic plant in Michigan, and construction is expected to start this year, according to its chief executive, Bill Brady. Mascoma already operates a smaller demonstration plant in Rome, N.Y."

To view full article click on below:

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study

Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study

March 29, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced it has made significant progress advancing CTP-499, its novel anti-inflammatory, anti-oxidant, and anti-fibrotic agent for diabetic nephropathy and other forms of chronic kidney disease, into clinical development. Based on encouraging preclinical results and successful formulation assessment in healthy volunteers, Concert has initiated a Phase 1 single ascending dose study of CTP-499 in healthy volunteers.

Selventa

Selventa Announces a Joint Technology Collaboration with Pfizer Inc., to Include Developing Knowledge-sharing Portal of Biological Networks for the Scientific Community

Selventa Announces a Joint Technology Collaboration with Pfizer Inc., to Include Developing Knowledge-sharing Portal of Biological Networks for the Scientific Community

March 28, 2011

CAMBRIDGE, Mass. – March 28, 2011 – SelventaTM today announced a continuation and expansion of its strategic partnership with the world’s largest pharmaceutical company, Pfizer Inc., in the areas of biological knowledge dissemination and drug safety.

Advanced Electron Beams, Inc

Advanced Electron Beams Introduces 2nd ITB Electron Beam Emitter for Aseptic Bottle Filling

Advanced Electron Beams Introduces 2nd ITB Electron Beam Emitter for Aseptic Bottle Filling

March 24, 2011

 

WILMINGTON, Mass., March 24, 2011 – Advanced Electron Beams (AEB), a leading provider of electron beam technology, today announced the introduction of the e16ITB emitter, their second “in the bottle” product for sterilizing PET and HDPE bottles. The e16ITB was designed specifically for the Asian market where the bottle geometries require a narrow nozzle emitter. Concurrent with this product announcement, AEB also announced that they have entered into a strategic agreement with a leading Japanese equipment OEM.